Healthcare Jun 23, 2021 08:04 AM (GMT+8) · EqualOcean
"Kechuangban daily" on the 23rd, the evening of June 22, China's State Drug Administration (nmpa) official website announced the latest, Baiji Shenzhou PD-1 antibody new drug tirelizumab two new indications (sdna) have been approved. According to a press release released by Baiji Shenzhou earlier, the two indications are: combined chemotherapy for the treatment of first-line advanced non squamous non-small cell lung cancer (NSCLC) patients and unresectable hepatocellular carcinoma (HCC) patients who have received previous treatment. So far, tirizumab has been approved five indications in China.